Lipidor Announces Last Patient Out in Calcipotriol/AKVANO spray (AKP01) Phase III Study Targeting Psoriasis
Lipidor AB (publ) today reports that the last patient has completed treatment in the phase III study evaluating the efficacy of using a sprayable calcipotriol product against mild to moderate psoriasis. Results from the study are expected to be presented in December 2019.
Lipidor has developed a sprayable calcipotriol product, Calcipotriol/AKVANO 50 µg/g cutaneous solution (AKP01), formulated with the company’s lipid-based technology in order to provide more precise dosing, increased comfort, and non-touch treatment to patients.
The phase III study is a comparative, randomized and placebo-controlled study with data collected from 277 patients treated at 14 clinics across India treated over a period of 8 weeks. The study compares the therapeutic equivalence of the calcipotriol spray with a marketed calcipotriol ointment.
The study is conducted in collaboration with Cerbios-Pharma SA, specialized in the development and manufacturing of chemical and biological APIs, and Cadila Pharmaceuticals Ltd of India, which is responsible for the study.
Psoriasis is a chronic disease in which the immune system plays a central part. The disease affects between 2 and 3 percent of the world’s population.
This information above was provided by Lipidor according to EU Market Abuse Regulations. The information was provided, through the below contact person, for publication on 7 November 2019 at 11.00am (CET).
For more information, please contact
Ola Holmlund, CEO, Lipidor AB
Phone: +46 72 50 70 369
Corpura Fondkommission AB
Telephone: +46 76 85 32 822
Lipidor AB (www.lipidor.se) is a Swedish, Stockholm-based research and development company with a pipeline of pharmaceutical development projects in preclinical and clinical phases. The Company develops topical medical products for the treatment of diseases such as psoriasis, bacterial skin infections and atopic dermatitis by reformulation of proven pharmaceutical substances.